Sandra P. D'Angelo, MD

Sandra P. D'Angelo, MD

Sarcoma Medical Oncologist & Cellular Therapist

My Role at MSK

Areas of Expertise

My Specialties

  • Sarcomas of Soft Tissue and Bone
  • Merkel Cell Carcinoma
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Associate Attending Physician
Get To Know Me

I am a medical oncologist specializing in the care of soft tissue sarcomas and bone sarcomas, as well as Merkel cell carcinoma

I work very closely with our multidisciplinary team of medical oncologists, surgeons, radiation oncologists, nurses, and patient support advocates to provide the best care and treatment for patients with these rare diseases. Our highly specialized team recognizes and appreciates the unique challenges that confront our patients, and we are all committed to addressing their needs. I partner with my patients and empower them while ensuring that they always get optimal care.

Read more

In my research, I am developing innovative ways to use immunotherapy to treat these cancers. I have designed and conducted numerous clinical trials of investigational therapies (drugs in development) that use the body’s immune system to attack multiple types of sarcoma. These include trials of immune checkpoint inhibitors, which “release the brakes” on the immune system, allowing it to fight tumors. Immune checkpoint inhibitors have been shown to be effective in the treatment of specific sarcomas, such as undifferentiated pleomorphic sarcoma, angiosarcoma, and dedifferentiated liposarcoma. I have also led clinical trials studying T cells engineered to recognize a specific molecule on synovial sarcomas and myloid round cell liposarcomas.

In my translational research (research done in the laboratory to develop new ways to diagnose and treat disease), I am investigating biomarkers predictive of benefit from systemic immunotherapy in patients with sarcoma. At MSK, we are at the forefront of sarcoma immunotherapy research and have already contributed to the field in meaningful ways while improving the lives of our patients.

My Role at MSK

A sarcoma medical oncologist is a cancer doctor who specializes in sarcoma. This includes soft tissue sarcomas (such as Ewing sarcoma and rhabdomyosarcoma) and benign (not cancer) growths that are like sarcoma.

A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.

Areas of Expertise

My Specialties

  • Sarcomas of Soft Tissue and Bone
  • Merkel Cell Carcinoma
Education & Honors

Education

  • MD, SUNY Downstate College of Medicine

Residencies

  • Internal Medicine - New York University
  • Internal Medicine - Memorial Sloan Kettering Cancer Center
  • Chief Residency (Internal Medicine) - Memorial Sloan Kettering Cancer Center

Awards and Honors

  • R01 CA259169-01A1, FDA (2022)
  • P50 CA217694 Career Enhancement Award (2020)
  • Sarcoma Foundation Alliance (2018)
  • Research Grant Recipient, Memorial Sloan Kettering Cancer Center Society (2015)
  • Career Development Award, Conquer Cancer, the ASCO Foundation (2015)
  • Alliance Scholar Award, Alliance for Clinical Trials in Oncology Foundation (2014)
  • Young Investigator Award, Conquer Cancer, the ASCO Foundation (2011)

Fellowships

  • Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Anthem BCBS and other BCBS licensee plans

In Network Coverage Type
PPO, POS, EPO, HMO

Anthem BCBS Health Plus

In Network Coverage Type
HMO

Anthem Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients
Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. D'Angelo sees patients at one location.

Office Phone
Location
New York, NY
160 East 53rd Street New York NY 10022

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Cellular Therapy Service doctors

See all Sarcoma Medical Oncology Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11. PMID: 29891538; PMCID: PMC8092079.

D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19. PMID: 29370992; PMCID: PMC6126546.

Read more

D’Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022 Jun 16;13(1):3477. doi: 10.1038/s41467-022-30874-8. PMID: 35710741; PMCID: PMC9203519.

D’Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021 Jul;9(7):e002646. doi: 10.1136/jitc-2021-002646. PMID: 34301810; PMCID: PMC8311489.

Rosenbaum E, Antonescu CR, Smith S, Bradic M, Kashani D, Richards AL, Donoghue M, Kelly CM, Nacev B, Chan JE, Chi P, Dickson MA, Keohan ML, Gounder MM, Movva S, Avutu V, Thornton K, Zehir A, Bowman AS, Singer S, Tap W, D’Angelo S. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J Immunother Cancer. 2022 Apr;10(4):e004149. doi: 10.1136/jitc-2021-004149. PMID: 35365586; PMCID: PMC8977792.

Publications on PubMed

Visit PubMed for a full listing of Dr. D'Angelo’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sandra P. D'Angelo discloses the following relationships and financial interests:

  • Adaptimmune
    Professional Services and Activities
  • GI Innovation Inc.
    Professional Services and Activities
  • Incyte
    Professional Services and Activities
  • Medendi
    Professional Services and Activities
  • Piper Sandler & Co.
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures